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Abstract 
SOX4, together with SOX11 and SOX12, forms the group C of SRY-related (SOX) transcription 
factors. They play key roles, often in redundancy, in multiple developmental pathways, including 
neurogenesis and skeletogenesis. De novo SOX11 heterozygous mutations have been shown to 
cause intellectual disability, growth deficiency, and dysmorphic features compatible with mild 
Coffin-Siris syndrome, but SOX4 disruption has not been associated with a human disease yet. 
Using trio-based exome sequencing, we here identify de novo SOX4 heterozygous missense 
variants in four children who share developmental delay, intellectual disability, and mild facial and 
digital morphological abnormalities. SOX4 is highly expressed in areas of active neurogenesis in 
human fetuses, and sox4 knockdown in Xenopus embryos diminishes brain and whole-body size. 
The SOX4 variants cluster in the highly conserved, SOX family-specific HMG domain, but each 
alters a different residue. In silico tools predict that each variant affects a distinct structural feature 
of this DNA-binding domain, and functional assays demonstrate that these SOX4 proteins 
carrying these variants are unable to bind DNA in vitro and transactivate SOX reporter genes in 
cultured cells. These variants are not found in the gnomAD database of individuals with 
presumably normal development, but twelve other SOX4 HMG-domain missense variants are 
recorded and all demonstrate partial to full activity in the reporter assay. Taken together, these 
findings point to specific SOX4 HMG-domain missense variants as the cause of a characteristic 
human neurodevelopmental disorder associated with mild facial and digital dysmorphism. 
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Introduction 
Corticogenesis and skeletogenesis are complex, tightly regulated developmental processes. 
Proper corticogenesis requires adequate production of neural progenitor cells, followed by 
guidance of these cells towards neurogenesis, and specialization into distinct, fully functional 
neuronal subtypes.1 In the human fetus, neural progenitors develop in the ventricular and 
subventricular zones of the nascent central nervous system.2 Starting on embryonic day 42,1 
these progenitors initiate their transition into proliferating neurons, which migrate outwards into 
the cortical mantle and commit to a post-mitotic differentiated state. This process is largely 
completed by birth. Similarly, proper skeletogenesis requires adequate production of multipotent 
progenitor cells, controlled migration and amplification of these cells, correct differentiation into 
chondrocytes, osteoblasts and other skeletal cell types, and coordinated activity of these and 
associated cell types. Skeletal progenitor cells arise from the neural crest and the paraxial and 
lateral plate mesoderm, and migrate into the future sites of the craniofacial, axial and appendicular 
skeleton by the fifth or sixth week of human embryo gestation.3 They subsequently amplify and 
commit to specific cell types to ensure proper skeleton patterning, size and function. Both 
neurogenesis and skeletogenesis are controlled at each step by unique genetic programs.1; 4; 5 
The uniqueness of these programs is determined by the combinations of transcription factors and 
other regulatory factors as much as by the factors themselves, as many of these factors contribute 
to distinct processes. To date, various types of developmental syndromes have been linked to 
genetic variants affecting the expression or activity of such factors, but the genetic origin of many 
diseases remains unknown.5; 6 
The family of SOX transcription factors gene is comprised of twenty members.7 Its first 
identified member, SRY, is encoded by the sex-determining-region of the Y chromosome. It 
features a DNA-binding domain related to that present in a class of high-mobility-group (HMG) 
proteins. SOX proteins are defined as having at least 50% identity with SRY in this so-called HMG 
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or SOX domain. Most SOX genes have been shown using in vitro assays and experimental animal 
models to have key roles in determining cell fate and differentiation in discrete lineages such that, 
altogether, the SOX family participates in the control of virtually all progenitor/stem and 
differentiated cell types. Mutations within and around several SOX genes have been associated 
with severe human syndromes. Among them, SRY (MIM: 480000) mutations cause XY sex 
reversal (MIM: 400044);8 SOX9 (MIM: 608160) mutations cause campomelic dysplasia 
(generalized chondrodysplasia; MIM: 114290) and XY sex reversal;9 SOX10 (MIM: 602229) 
mutations cause Waardenburg-Shah syndrome (pigmentary abnormalities, hearing loss, and 
Hirschsprung disease; MIM: 277580);10 and SOX5 (MIM: 604975) mutations cause Lamb-Shaffer 
syndrome (intellectual disability, behavior abnormalities, and dysmorphic features; MIM: 
616803).11 Beside SRY and SOX3 (MIM: 313430), all SOX genes are located on autosomal 
chromosomes, and disease-causing mutations were determined in virtually all cases to be 
inactivating, heterozygous and de novo. Most SOX-related diseases have thus been proposed to 
be due to gene haploinsufficiency. They are not nearly as severe as the phenotypes of mice 
lacking both gene copies, but their major impact on affected individuals has demonstrated the 
importance of carrying two intact gene copies for normal development. To date, mutations in 
almost a dozen of the twenty SOX genes have not been associated with a human disease yet. 
SOX4 (MIM: 184430) is among these genes. 
SOX4, together with SOX11 (MIM: 600898) and SOX12 (MIM: 601947), forms the SOXC 
group, one of the eight groups that compose the SOX family.12; 13 The three SOXC proteins have 
almost identical DNA-binding domains and are also highly conserved in their other known 
functional region, a transactivation domain located at their C-terminus. Their genes overlap in 
expression in many cell types and are most active in progenitor cells. SOX12 has a weak 
transactivation domain and is dispensable for mouse development and adult physiology.2; 13-18 In 
contrast, knockdown of either sox4 or sox11 in Xenopus laevis embryos causes microphthalmia 
 5 
 
with or without coloboma.19 Homozygous inactivation of Sox4 in the mouse is lethal at embryonic 
day 14 (early fetal stage) due to heart malformation20, and Sox11 inactivation is lethal at birth due 
to marked underdevelopment of such vital organs as the heart, spleen and lungs.17 Combined 
inactivation of Sox4 and Sox11 is lethal at embryonic day 10.5 due to a block in early 
organogenesis.15 Conditional gene inactivation studies have revealed additive and redundant 
roles for Sox4 and Sox11 in many developmental processes. During cerebral cortex formation, 
Sox4 and Sox11 are most highly expressed in intermediate progenitor cells.2 Sox4 inactivation 
affects the maintenance of these cells, and Sox11 inactivation reduces their proliferation and 
differentiation, resulting in a small brain with a thin cerebral cortex at birth.2 Combined inactivation 
of the two genes drastically impairs neuronal progenitor cell survival15 and activation of key 
neuronal differentiation genes.21 Regarding skeletogenesis, single inactivation of Sox4 or Sox11 
in progenitor cells has mild if any consequences, whereas simultaneous inactivation of both genes 
severely reduces cell survival and affects downstream lineage specification, leading to abnormal 
patterning, growth and maturation of skeletal primordia.22; 23 In humans, de novo SOX11 missense 
variants abolishing the DNA-binding capability of SOX11 have been associated with a 
neurodevelopmental disorder whose features ± microcephaly, global developmental delay, 
intellectual disability, and facial and digital abnormalities ± are compatible with mild Coffin-Siris 
syndrome (CSS; MIM: 135900).24; 25 Together, these findings make it plausible that SOX4 variants 
might also cause a human disease that has still to be singled out. 
Here we report four individuals that carry distinct heterozygous de novo missense variants 
in SOX4 and that share global development delay, mild to severe intellectual disability (ID), facial 
dysmorphism, and fifth finger clinodactyly. Along with data from SOX4 RNA profiling in humans, 
sox4 knockdown assays in Xenopus embryos, in silico predictions of protein structural damage, 
and functional assays for transcriptional activity in vitro, these findings concur that SOX4 is a 
critical gene for human global, intellectual and skeletal development. 
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Materials and Methods 
Ascertainment of De Novo SOX4 Sequence Variants and Statistical Analyses 
Subject 1 was identified through trio-based exome sequencing performed on subjects with 
syndromic ID at the University of Washington Center for Medical Mendelian Genomics (UW-
CMG). Parents provided consent according to the IRB protocol 3206/2016 at Policlinico S. Orsola-
Malpighi (Bologna, Italy). Three other subjects were discovered through trio-based exome 
sequencing performed as part of the Deciphering Developmental Disorders (DDD) study (data 
freeze of 4296 children).6 The DDD study had UK Research Ethics Committee approval 
(10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic 
of Ireland REC). Consent for publication of photographs was obtained from the parents of subjects 
1, 2 and 4. The occurrence of SOX4 missense variants in neuro-developmental disorders and the 
clustering of these variants were assessed using DenovolyzeR26 and CLUMP,27 respectively.  
 
In Silico Assessment of SOX4 Variant Pathogenicity 
Evolutionary conservation of the SOX4 HMG-domain sequence was assessed with MacVector16 
software using human and vertebrate orthologous sequences retrieved from the National Center 
for Biotechnology Information (NCBI) protein database (Tables S1 and S2). The presence of 
variants in the SOX4 coding sequence in the human healthy population was queried using the 
ExAC and gnomAD browser.28 The effects of missense variants on protein structure and function 
was predicted using the PolyPhen-2,29 HOPE,30 and SWISS-MODEL online tools.31  
 
Assessment of SOX4 Expression in the Human Brain 
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Variations in SOX4 transcript levels in the human brain between different developmental stages 
and anatomical regions were investigated using RNA-seq and RNA microarray data from the 
BrainSpan Atlas of the Developing Human Brain.32 
 
sox4 Knockdown in Xenopus Embryos 
Xenopus laevis embryos were generated, staged and cultured according to standard protocols.33 
For loss-of-function experiments, 40 ng of sox4 morpholino oligonucleotide (MO) or control MO 
(GeneTools, LLC, OR, USA) was injected into both dorso-animal blastomeres to target anterior 
neural tissue.19; 33; 34 The specificity of the sox4 MO was previously demonstrated by showing that 
the morphant phenotype could be rescued by co-injection of a human SOX4 construct.19 GFP 
RNA (0.5 ng) was co-injected as a lineage tracer.19 Embryos were collected at stage 43 and then 
either fixed with formaldehyde for whole-mount analysis or euthanized with ethyl 3-
aminobenzoate methanesulfonate (5-10 g/l; Sigma-Aldrich) for brain analysis. Embryos and 
brains were imaged using a Zeiss Axiophot microscope. All measurements were done using NIH 
ImageJ software and compared using the Mann-Whitney U test (GraphPad prism). 
 
Functional Assessment of SOX4 Variants in vitro 
SOX4 mutations were introduced into a mouse 3FLAG-SOX4 expression plasmid23 using 
QuikChange Site-Directed Mutagenesis (Stratagene) and appropriate DNA primers (Table S3). 
Capillary sequencing was used to verify the SOX4 wild-type and variant sequences. A mouse 
POU3F2 expression plasmid and a 6FXO-p89Luc reporter plasmid were as described.12 
To assess the expression level and intracellular localization of SOX4 variants, COS-1 cells 
were plated at 300,000/well (6-well plates) in 2 ml of DMEM medium supplemented with 10% 
FCS. Eight hours later, they were transfected with mixtures containing ȝJRIHPSW\ or SOX4 
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H[SUHVVLRQSODVPLGDQGȝORI)X*(1(3URPHJD7KHQH[WGD\Fytoplasmic and nuclear 
extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo 
Fisher Scientific). They were tested by western blotting under standard conditions. Briefly, 1 ȝORI 
extract was subjected to 8% SDS-PAGE and transferred to PVDF membranes using iBLOT 2 Gel 
Transfer Device (Thermo Fisher Scientific). Membranes were blocked in Tris-Buffered Saline with 
0.1% (v/v) Tween 20 (TBST) and 5% (w/v) nonfat dry milk for 1 h and then incubated overnight 
at 4°C in blocking solution containing a 1:25,000 dilution of peroxidase-conjugated  anti-FLAG M2 
antibody (Sigma-Aldrich, A8592). FLAG-SOX4 signals were visualized on X-ray films using 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). 
The same extracts were used to assess the ability of SOX4 variants to bind DNA. 
Electrophoretic mobility shift assays (EMSAs) were carried out essentially as described.12 Briefly, 
10 fmoles RI);2SUREH ODEHOHGZLWK >Į-32P]-dCTP was LQFXEDWHGZLWKȝO RI F\WRSODVPLF or 
QXFOHDUH[WUDFWLQWKHSUHVHQFHRIȝJRISRO\(dG-dC).poly(dG-dC) (Sigma-Aldrich). Reactions 
were incubated for 30 min and protein/DNA complexes were resolved by electrophoresis under 
native conditions. Gels were exposed overnight to X-ray films at -80°C.  
The transactivation capability of SOX4 variants was tested essentially as described.12 
Briefly, COS-1 cells were transiently transfected with mixtures containing 500 ng of 6FXO-p89Luc 
reporter, 150 ng of pSV-beta-galactosidase (Promega), 0 or 150 ng of 3FLAG-mSOX4 and 
POU3F2 expression plasmids, and empty expression plasmid for a total of 1 ȝJRI'1$)RUW\
hours later, cell extracts were made iQȝORI7URSL[/\VLVEXIIHUsupplemented with 0.5 mM 
DTT (Applied Biosystems) and protease inhibitor cocktail (Thermo Fisher Scientific). Extracts 
were tested in Dual-Light luciferase and beta-galactosidase assay (Thermo Fisher Scientific). 
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Results  
SOX4 is under Marked Sequence Conservation Constraint in Humans 
SOX4 mutations have not been associated with a developmental disease in humans yet, but 
genomic information recently collected for the general human population provides evidence that 
the gene is under tight sequence conservation constraint and is thus likely critical for normal 
development. The Exome Aggregation Consortium database (ExAC), which contains exome 
sequences for 60706 unrelated human individuals with no history of severe pediatric disease, 
indeed indicates that while 196.6 missense variants were expected for SOX4, only 90 were 
observed, for a constraint z-score of 3.72. Furthermore, while 4.6 loss-of-function (non-sense) 
variants were expected, only 1 was observed, resulting in a probability of loss-of-function 
intolerance of 0.38. We then used the Genome Aggregation database (gnomAD), which provides 
genomic information for 138632 individuals, including those from the ExAC database, to analyze 
the distribution of SOX4 variants in the presumably normal human population. Synonymous and 
missense variants were present throughout the SOX4 coding sequence (Figure 1A and 1B). The 
N-terminal and central regions of the protein, which are not known to be functionally involved, 
exhibited more missense variants than synonymous variants (3663 versus 2926; Figure 1C), 
whereas the DNA-binding and transactivation domains displayed fewer missense variants than 
synonymous variants (12 versus 216, and 17 versus 61, respectively). These differences, 
however, were not statistically significant in two-sample t-tests, likely because the numbers of 
variants varied greatly per amino acid. Similar tests performed for the percentages of residues 
per domain featuring at least one variant also failed to detect statistically significant differences 
for synonymous variants between the HMG, transactivation and other domains (Figure 1D). In 
contrast, the percentages of residues with at least one missense variant were significantly much 
lower in the HMG domain (p=0.004) and lower in the transactivation domain (p=0.024) than in the 
other domains. Together with the fact that each of the twelve missense variants located in the 
 10 
 
HMG domain was detected in a single individual and in the heterozygous state, these data 
suggest that genomic variants in the SOX4 HMG domain might seldom be compatible with normal 
development, even in the heterozygous state. Supporting this conclusion, no deletions of SOX4 
were identified in a recently published copy-number-variant map of the human genome in normal 
individuals.35 
 
Identification of Four Subjects with a Neurodevelopmental Syndrome and SOX4 Variants 
A first child presenting with severe developmental delay, ID and other clinical features was found 
through trio-based exome sequencing to carry a de novo missense SOX4 variant 
(g.chr6:21594963C>A [hg19], c.198C>A [p.Phe66Leu]. Three other children with a similar 
disease and also carrying a de novo SOX4 missense variant were identified through the 
Deciphering Developmental Disorders (DDD) study (g.chr6:21595099G>C, c.334G>C 
[p.Ala112Pro]; g.chr6:21594941T>G, c.176T>G, [p.Ile59Ser]; g.chr6:21595080G>T, c.315G>T, 
[p.Lys105Asn], GenBank: NM_003107.2). These four subjects were from unrelated families and 
their SOX4 variants were distinct. Detailed case reports can be found in Supplemental Note and 
a summary of clinical findings in Table 1. In brief, all four children had global development delay 
and ID, but at varying degrees, case 2 being very severe, case 1, severe, case 4, mild, and case 
3, very mild. All also had characteristic facial dysmorphism, with anteverted nares, wide mouth 
with a cupid bow, and posteriorly rotated ears, and fifth-finger clinodactyly (Figure 2). Additionally, 
the most severely affected children had hypotonia and other clinical features, such as ventricular 
septal defect (case 1) and spastic quadriparesis (case 2). 
 Based on these findings, we asked whether the occurrence of de novo SOX4 missense 
variants in individuals with a neuro-developmental disorder was significant. We used 
denovolyzeR,26 an integrated toolset for the analysis of sporadic genetic sequence variants, and 
applied it to all cases identified in the 4293 DDD probands, as reported in denovo-db 1.6.1.36 We 
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found after multiple-testing correction with the Bonferroni method for 19618 genes that the 
occurrence of de novo SOX4 missense variants was statistically significant (p = 0.012). 
Together, these data strongly suggest that SOX4 missense variants underlie a specific form of 
human neurodevelopmental disorder associated with mild dysmorphism. 
  
SOX4 Is Strongly Expressed in Actively Developing Regions of the Human Brain 
To add support to the proposition that SOX4 may be critical for human brain development, we 
examined its gene expression in specific regions of the human brain using RNA-seq and RNA-
microarray data available in the BrainSpan Atlas of the Developing Human Brain.32 SOX4 
expression was found to be high in all brain regions examined (dorsolateral prefrontal cortex, 
striatum and cerebellar cortex) during the first two trimesters of embryonic gestation, and then to 
decrease progressively to reach a very low level by the 3rd and 4th decades of postnatal life (Figure 
3A-C). SOX4 expression was higher in areas of very active neurogenesis, including the ventricular 
and subventricular zones, than in less active areas, such as the cortical plate and subplate (Mann-
Whitney U-test p<0.01) (Figure 3D). While not proving that SOX4 has important functions in 
human brain development, these expression data nevertheless constitute a necessary argument 
to support the notion that SOX4 may directly control the development of several regions of the 
human brain. 
 
sox4 Knockdown in Xenopus Embryos Interferes with Brain and Whole-Body Development 
To functionally test the importance of SOX4 in brain development in vivo, we knocked down its 
ortholog in Xenopus laevis embryos using a well-described Morpholino oligonucleotide (MO).19  
We injected either a control or a sox4 MO in the dorso-animal blastomeres of 8-cell-stage embryos 
to target anterior neural tissue.34 We previously reported that sox4 morphants had microphthalmia 
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at stage 43.19 Further analysis revealed that they also had microcephaly and small bodies (Figure 
4A and 4B). The reduced size of the brain in mutants compared to controls reflected 
underdevelopment of the forebrain and midbrain, but not hindbrain (Figure 4C). These data thus 
suggest that SOX4 may also significantly participate in neurogenesis and other aspects of 
embryonic development in humans. 
 
The Subjects¶SOX4 Missense Variants Cluster in the HMG Domain and Are Not Found in 
Control Individuals 
The SOX4 missense variants identified in the four subjects were all located in the HMG domain 
(Figure 5A). This apparent clustering of variants was striking considering that missense variants 
in this domain were found to be significantly underrepresented in the control human population. 
We therefore asked whether it was statistically significant. We compared the locations of the 
VXEMHFWV¶ missense variants to the location of gnomAD missense variants using the Python 
program CLUMP (CLUstering of Mutation Position), which implements a case-control statistical 
approach.27 Since our four cases¶YDULDQWVZHUHQRYHOZHused only singleton variants as controls. 
Upon performing 10K permutations and correction for multiple testing with the Benjamini-
Hochberg method, we obtained a statistically significant difference (p-value = 0.017) between the 
average score of the four cases (1.04) and that of controls (3.73). This result thus supports the 
proposition that disease-causing SOX4 variants cluster in the HMG domain. 
 TKHIRXUVXEMHFWV¶YDULDQWVZHUHGLVWLQFW from those reported in gnomAD and they affected 
residues fully conserved in SOX4 vertebrate orthologs (Figure 5B). Moreover, Phe66 and Lys105 
are conserved in all human SOX proteins; Ala112 is replaced by Gln in the SOXD group, but is 
otherwise conserved in all human SOX proteins; and Ile59 is fully or semi-conserved in all human 
SOX proteins (Figure 5C). Two of the twelve gnomAD variants affected the same residues as 
those in subjects 2 and 4, but they were different (Lys105Arg instead of Lys105Asn, and 
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Ala112Thr instead of Ala112Pro); two others also affected highly conserved residues (Met67Leu 
and Pro107Ser); but the other eight affected residues poorly conserved in the SOX family (Figure 
5B and C). Further, three of the latter matched wild-type residues in other SOX proteins 
(Lys101Thr, Ser103Gly and Arg129Gln). 7KXV XQOLNH WKH FDVHV¶ YDULDQWV RQO\ D VXEVHW RI
gnomAD variants affected highly conserved residues. 
Since variants in other SOX HMG domains have been associated with disease, we asked 
whether some of them matched those detected in our subjects (Table 2). SRY variants in residues 
equivalent to those affected in our subjects were shown to cause disease, but only one 
(Phe112Leu) fully matched a SOX4 variant (Phe66Leu). Variants in residues equivalent to Phe66, 
Ala112, and K105 in SOX4 were also shown in SOX genes located on autosomal chromosomes, 
namely SOX9, SOX10, or SOX11, to cause disease at the heterozygous state. Again, only one 
(Lys150Asn in SOX10) resulted in the same substitution as in SOX4 (Lys105Asn). No disease-
causing mutation in the residue equivalent to Ile59 in SOX4 has been reported for SOX genes 
located on autosomal chromosomes. Since Ile59Ser was detected in the least affected child 
(subject 3), it is conceivable that a heterozygous missense mutation of this residue might also be 
on the benign or mild-disease side for other SOX genes. We performed the same analysis for the 
twelve SOX4 HMG-domain gnomAD variants (Table S4). In brief, five SOX4 gnomAD variants 
affected residues that had no reported variant or only gnomAD variants in other SOX genes. The 
seven others had at least one disease-causing variant in another SOX gene, but only one was a 
fully match: Ala112Thr in SOX4, Ala113Thr in SRY, and Ala158Thr in SOX9. Collectively, these 
findings support the notion that the IRXUVXEMHFWV¶SOX4 variants are likely pathogenic and that at 
least a subset of SOX4 gnomAD variants might also be pathogenic. This conclusion for the latter 
is plausible since the gnomAD database was established by excluding individuals with severe 
pediatric disease, leaving open the possibility that it includes individuals with mild, unreported 
disease.    
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In silico Analyses Predict Damaging Structural Consequences for the Four 6XEMHFWV¶SOX4 
variants 
The crystal structure of the SOX4 HMG domain bound to DNA was previously solved and shown 
to be very similar to that of other SOX proteins.37 Complementary assays in vitro for several SOX 
proteins have validated and extended the acquired knowledge by demonstrating which residues 
are critical for DNA binding, DNA bending, and protein shuttling between the cytoplasm and 
nucleus.7 Valuable analyses can therefore be made in silico to try and predict the 
consequences of missense variants on the structure and hence function of the SOX4 HMG 
domain. The phenylalanine changed into leucine in Subject 1 (Phe66Leu) belongs to the so-called 
FM wedge, a protein motif intercalating within the minor groove of DNA and conferring on the 
SOX domain one of its characteristic properties, which is to bend DNA (Figure S1A and S1B).37 
Both phenylalanine and leucine are hydrophobic, but leucine has a short aliphatic chain whereas 
phenylalanine has a large aromatic chain (Figure S1C). The HOPE tool30 predicted that this chain 
difference could disrupt protein function. The alanine residue changed into proline in Subject 2 
(Ala112Pro) is located within the third of three D-helices that confer on the SOX domain an L-
shape essential for DNA binding (Figure S1A and S1B). The replacement of a small hydrophobic 
amino acid by a larger, more rigid residue was predicted to remove a hydrogen bond and thereby 
to destabilize the helix (Figure S1D). The isoleucine residue changed into serine in Subject 3 
(Ile59Ser) occupies the second position in the N-terminus of the SOX domain, close to two 
residues critical for DNA binding (His58 and Arg61). The Ile59Ser variant introduces a residue 
that is smaller and less hydrophobic than the wild-type residue and that might therefore destabilize 
the local E-strand configuration and disrupt hydrophobic interactions in the core of the protein or 
on its surface (Figure S1E). The lysine residue changed into asparagine in Subject 4 (Lys105Asn) 
is located in the middle of the third D-helix of the SOX domain (Figure S1A and S1B). The 
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replacement of a large, positively charged residue by a smaller, neutral residue was predicted to 
disrupt a salt bridge and hence the wild-type D-helical structure (Figure S1F).  
In line with the HOPE predictions, PolyPhen-2 (Polymorphism Phenotyping v2), a tool that 
predicts possible impact of missense variants on the structure and function of a protein using 
straightforward physical and comparative considerations,29 foresaw that three variants would be 
highly damaging (Ile59Ser: score of 0.997; Ala112Pro: score of 1; Lys105Asn: score of 0.99) and 
that the fourth one could be damaging (p.Phe66Leu: score of 0.499).  
We applied the same prediction tools to the twelve SOX4 gnomAD variants. In brief, 
considering the location of the residues in the HMG domain with respect to the functional motifs 
(Figure S2A), the conservation of the residues in SOX proteins and the change in side-chain type 
caused by the variants (Figure S2B and C), three variants stood out as being most likely to be 
pathogenic: Met67Leu, Pro107Ser and Ala112Thr. It is worth noting that all three residues cause 
disease when mutated in other SOX proteins but, as mentioned earlier, only Ala112Thr has known 
disease-causing matches (Table S4).  
In conclusion, in silico tools predict that all SOX4 subject variants, but only a subset of 
gnomAD variants, could damage the structure and hence the activity of the SOX4 HMG domain.  
 
The Four SXEMHFWV¶SOX4 Variants Are Unable to Bind DNA and Transactivate 
To test the functional impact of RXUVXEMHFWV¶missense mutations, we generated a mammalian 
expression plasmid for each variant. When transiently transfected into COS-1 cells, the plasmids 
for the wild-type and four variants led to similar amounts of SOX4 in the cytoplasmic and nuclear 
compartments (Figure 6A), indicating that the missense mutations did not affect SOX4 synthesis, 
stability and nuclear translocation. We then performed electrophoretic mobility shift assays to test 
the ability of the variants to bind DNA. We used an FXO DNA probe previously shown to bind 
 16 
 
SOX4 efficiently.12 This probe corresponds to a minimal FGF4 enhancer sequence (F) and 
features a SOX-binding site (X) adjacent to a POU-domain-binding site (O).38 Wild-type SOX4 
formed a stable complex with the probe, as expected, but none of the variants did (Figure 6B). 
This result implies that the mutations sufficiently altered the structure of the HMG domain to 
prevent the variant proteins from binding to DNA in vitro.  
We next asked if the variants could activate transcription in intact cells. We transiently 
transfected COS-1 cells with a reporter plasmid containing six tandem copies of the FXO 
sequence12 along with plasmids encoding no protein (empty), SOX4 wild-type or variants, and 
POU3F2 (also known as BRN-2). As shown previously,12 wild-type SOX4 and POU3F2 activated 
the reporter weakly when expressed singly, and synergized to reach a high level of activation 
when co-expressed (Figure 6C). In contrast, none of the SOX4 variants could transactivate the 
reporter by itself or in synergy with POU3F2.  
We then tested the SOX4 gnomAD variants in our reporter assay. Like wild-type SOX4, 
all twelve variants were well expressed in COS-1 cells (Figure S3). Interestingly, eleven of them 
were as competent or up to twice as competent as wild-type SOX4 in activating the reporter in 
synergy with POU3F2 (Figure 6D). The twelfth one, Ala112Thr, was four-fold less efficient than 
wild-type SOX4, but was still nine times as active as the Ala112Pro variant found in subject 2.  
These functional assays in vitro thus suggest that our four subjects developed a disease 
due at least in part to inability of their SOX4 variant to function as transcription factors. They also 
suggest that the individuals carrying the gnomAD variants had normal development, except 
perhaps the Ala112Thr carrier.  
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Discussion 
The present study links SOX4 variants to a human developmental disease. We reported four 
unrelated children who presented with global developmental delay and intellectual disability 
associated with distinctive dysmorphic features. Each child was heterozygous for a different de 
novo SOX4 missense variant and none of these variants was detected in a large cohort of 
presumably healthy individuals. They significantly clustered in the HMG domain and were 
predicted in silico to drastically alter the structure of this domain. Functional assays in vitro 
documented their inability to bind DNA and activate transcription. Based on these data and 
evidence that SOX4 is highly expressed in the developing human brain and necessary in animal 
models for brain development, we propose that reduced expression of SOX4 target genes at 
critical points in embryonic and early postnatal development of the subjects led to the 
neurodevelopmental syndrome and associated dysmorphic features. 
The HMG domain is the common feature and primary functional region of all SOX 
proteins.7; 39 Almost 50% of the 76 residues that compose this domain are conserved in all twenty 
human SOX proteins.40-42 These residues confer on the proteins their abilities to bind and bend 
DNA, to shuttle between the cytoplasm and nucleus, and to interact with other proteins. Numerous 
missense variants in SRY and other SOX genes have been associated with severe disease in 
humans, and in most cases, the variants were located in the HMG domain. Thus, that our subjects¶
SOX4 variants were located in the HMG domain and affected critical residues, whereas SOX4 
variants in this domain are significantly underrepresented in the general population, was a first 
and solid hint of possible pathogenicity. The most solid piece of evidence that we obtained in favor 
of pathogenicity was that none of our four subjectV¶ variants was able to transactivate a reporter 
gene in vitro, whereas eleven of the twelve variants detected in the HMG domain in gnomAD 
exhibited similar activity as wild-type SOX4. Even the twelfth one retained significant activity 
compared to the subjectV¶ variants. In silico analyses of structural consequences of the variants 
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had predicted damaging consequeQFHVIRUDOOVXEMHFWV¶YDULDQWVEXWDOVR IRUVHYHUDOJQRP$'
variants. Our reporter assay thus appears as a more reliable predictor of pathogenicity for SOX4 
variants in the HMG domain than current in silico tools. As genetic testing becomes more and 
more customary in the future, we surmise that more SOX4 variants will be identified in individuals 
with neurodevelopmental disease and possibly other disorders and that our reporter assay will be 
instrumental in helping discern pathogenic from nonpathogenic mutations.  
Our subjects suggested that the spectrum of severity of the neurodevelopmental disorder 
due to SOX4 variants is likely wide. No other disruptive variants that could explain the wide range 
of disease severity were identified in these children. Genotype-phenotype correlations are not 
evident at the moment and, as in many other genetic disorders, the causes of the wide range of 
clinical severity have yet to be elucidated. We envision two possible scenarios. The first is that 
the SOX4 variants may have different impacts in vivo, despite having similar damaging 
consequences in our functional assays in vitro. The second is that variants in other genes, which 
were not flagged as possibly pathogenic, or in gene regulatory regions outside the exome may 
contribute to aggravating or lessening the impact of SOX4 variants on development. The analysis 
of multiple children carrying the same and additional SOX4 variants should help answer this 
question. Also, the sophistication of in silico prediction tools and the refinement of functional 
assays in animal models and in vitro, which would test SOX4 variants in a more physiological 
context, should also be helpful.   
The neurodevelopmental defects of our four cases were detected from early infancy and 
were consistent with impaired development of the cerebral cortex, a region of the brain 
considerably more developed in humans than in other mammals and involved in such higher-
order functions as thinking, cognition, memory, attention and language. Neurogenesis is largely 
complete by mid-gestation, and a lifetime maximum number of neuronal connections are 
established by three years of age.43 In keeping with the proposition that SOX4 is likely to have 
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important roles in development of the human cerebral cortex, we showed that SOX4 transcript 
levels were highest in the brain during early fetal development, steadily declined during postnatal 
life, and were lowest past the age of 20 years. We also showed that the expression of SOX4 in 
the brain of 21-week-old fetuses was highest in neurogenic niches.  
All four subjects were small for their age and exhibited mild but distinct facial dysmorphism 
and fifth finger clinodactyly. Their small stature could have several origins since SOX4 was shown 
in animal models to have important roles in multiple processes. These processes include 
skeletogenesis and, strikingly, the morphological parameters of our children bear resemblance 
with those of mice lacking the SOXC genes specifically in skeletal cells. Inactivation of Sox4, 
Sox11, or both genes in differentiated chondrocytes impaired skeletal growth.44 Inactivation of 
either Sox4 or Sox11 in skeletal progenitor cells affected growth.23 Facial and digital defects 
matching those of our subjects were not noted, but might have been overlooked. Notably, 
inactivation of both Sox4 and Sox11 in skeletal progenitor cells resulted in complete failure of 
skeletal primordia growth, articulation and ossification. Clinodactyly, craniofacial dysmorphism, 
and short stature of our subjects could thus be due to a reduction in the global activity of SOX4 
in skeletal cells. 
The first process discovered to be impacted by Sox4 inactivation in the mouse is outflow 
track formation.20 Sox4-null mouse embryos indeed die in utero from heart septation defects 
known as common arterial trunk in humans. One can thus ponder that a reduction in SOX4 activity 
due to haploinsufficiency or another mechanism contributed to the peri-membranous ventricular 
septal defect detected in our subject 1. This abnormality was not reported in the other individuals, 
nor was it reported in Sox4+/- mice, suggesting that its penetrance is influenced by genetic 
background. With this in mind, as well as evidence from animal studies that SOX4 impacts many 
processes, close follow-up of individuals with SOX4 variants predicted to be damaging should be 
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recommended to determine whether the variants predispose to cardiac and other problems 
besides neurological and skeletal issues in development and beyond.    
The target genes of SOX4 in the development of the brain, skeleton and other organs 
have not yet been fully defined. In mouse intermediate cortex progenitor cells, SOX4 was shown 
to transactivate Tbr2, a gene required in the mouse to produce adequate numbers of neurons in 
each cortical layer.2 45 In cultured mouse neuronal stem cells, SOX4 was able to activate a DCX 
(MIM: 300121) reporter gene.14 DCX mutations are associated in humans with cortical 
malformations.46 Acting largely in redundancy, mouse SOX4 and SOX11 were found to activate 
a transcriptional program critical to specify the identity and connectivity of corticospinal neurons.16 
They were also shown to control skeletal cell fate and differentiation by promoting signaling 
pathways of major importance in many processes, including canonical and non-canonical WNT 
signaling.23; 44 A genome-wide analysis of SOX4 targets in prostate cancer cells identified multiple 
genes of potential relevance to neuronal, skeletal and many other processes.47 For example, 
SOX4 was shown to regulate WDR45 (MIM: 300526), a gene associated with neurodegeneration 
and iron accumulation in the brain; multiple components of the RNA-induced silencing (RISC) 
complex; and several genes involved in the transforming growth factor-E, Hedgehog, Notch and 
WNT pathways. SOX4 variants thus have a clear potential to affect the expression of important 
genes in neurodevelopment, skeletogenesis, and other processes.  
The close relationships existing between SOX4 and SOX11 make it relevant to compare 
the current work with earlier reports that associated SOX11 mutations with a form of mild Coffin-
Siris syndrome.24; 25 For both SOX4 and SOX11, missense variants found in subjects were located 
in the HMG domain25 and functional studies indicated that the variant proteins lacked 
transcriptional activity. In both cases, individuals exhibited mild to severe intellectual disability, 
growth deficiency, specific dysmorphic facial features, and fifth-finger clinodactyly. Several 
SOX11 subjects were also described to have hypoplastic fifth-toe nails, which was seen in one of 
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our SOX4 individuals, and syndactyly of the 2nd and 3rd toes, which was not seen in any of our 
cases. Thus, SOX4 and SOX11 mutations result in a series of similar clinical characteristics, but 
not all defects are alike in nature, penetrance and severity. This finding is consistent with the 
overlapping expression patterns of the human SOX4 and SOX11 genes in development, and with 
the similar, but not identical activities of the SOX4 and SOX11 proteins. A full description and 
comparison of the clinical phenotypes of larger cohorts of individuals will be helpful in the future 
to more precisely define the extent of neurodevelopmental, skeletal and other clinical features 
caused by pathogenic variants in SOX4 and SOX11 and the degree of similarities and 
dissimilarities between the two types of diseases. Based on all data currently available, we 
propose that non-functional variants in SOX4 and SOX11 may cause a novel class of syndromes 
that have overlapping clinical features, notably in neurodevelopment and skeletogenesis. 
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Figure Legends 
Figure 1. Analysis of SOX4 Missense Variants in the gnomAD Control Cohort 
(A) Bar graphs showing the numbers of synonymous and missense SOX4 variants detected in 
gnomAD for each amino acid of the SOX4 protein sequence. The HMG domain is highlighted in 
yellow and the transactivation domain in grey. 
(B) Comparison of the numbers of synonymous and missense gnomAD variants in the different 
SOX4 domains. Columns correspond to the N-terminal and central region (Nt + Ce), HMG domain 
(HMG) and transactivation domain (TA).  Values are indicated at the top of each column. 
(C) Percentages of residues per SOX region that feature at least one gnomAD variant. The p-
values obtained in two-sample t-tests for the comparison of regions is shown. 
 
Figure 2. Pictures of Subject 1 at 4 Years and 8 Months (A), Subject 2 at 6 Years and 10 
Months (B), and Subject 4 at 6 Years and 10 Months of Age (C). Frontal and profile views of 
the heads show mild facial dysmorphism, including anteverted nares, wide mouth with a cupid 
bow, and posteriorly rotated ears. Pictures of the hands of subjects 1 and 4 show bilateral 5th 
finger clinodactyly. A picture of the feet of subject 1 shows normal morphology. 
 
Figure 3. SOX4 Transcript Levels in the Developing and Adult Human Brain  
(A to C) Changes in SOX4 expression levels during development and adult life in the dorsolateral 
prefrontal cortex, striatum, and cerebellar cortex, as assessed by RNA-seq. The first three 
samples were obtained during the three trimesters of fetal development, and the next three during 
the first four decades of life, as indicated on the X-axis. No data were available for the cerebellar 
cortex in the first trimester of embryogenesis. 
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(D) RNA microarray data demonstrating that SOX4 expression is significantly higher in 
neuroanatomical regions with high-level neurogenesis (ventricular and subventricular zones) than 
in regions with low-level neurogenesis (subplate and cortical plate) at 21 weeks of gestation 
(Mann-Whitney U-test, p<0.01). 
 
Figure 4. Effect of sox4 Knockdown on Xenopus laevis Embryo Development 
(A) Top, representative pictures of stage-43 Xenopus embryos showing that bilateral injection of 
sox4 MO leads to a smaller head area (white dotted circles) and to microphthalmia compared to 
bilateral injection of control MO. Bottom, graph showing quantification of the head area for all 
tested embryos. n, number of embryos. The p-value was calculated by a non-parametric Mann-
:KLWQH\UDQNVXPWHVWS6FDOHEar, 1 mm. 
(B) Sox4 depletion results in shorter body length. Data are presented as in panel A. ****, p 
6FDOHEDUPP 
(C) Sox4 deficiency impairs brain development. Top left, pictures showing that sox4 MO injections 
lead to a small brain area (dotted line). Top right, pictures showing that Sox4 depletion results in 
underdevelopment of the fore- and mid-brain, but not hindbrain (white vertical lines separated by 
a horizontal dotted line). Bottom panels, data quantification performed as in panel A. n, number 
RIHPEU\RVSSQVQRWVLJQLILFDQW 
 
Figure 5. Analysis of the Location of SOX4 Missense Variants Detected in Subjects and in 
gnomAD Individuals 
(A) Schematic of the human SOX4 protein showing the location of the four subject missense 
variants in the HMG domain. Variants are shown in red and their positions are marked with bars. 
Numbers indicate the position of amino acids in the protein sequence.  
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(B) Alignment of the SOX4 HMG-domain sequences from various vertebrate species. Sequence 
accession numbers are listed in Table S1. SOX4 variants found in the study subjects and in the 
gnomAD control cohort are shown in red and purple, respectively, above the sequences, and 
amino acids matching the variants are similarly colored in the aligned sequences. Above the 
sequences, symbols denote fully conserved (asterisks) and semi-conserved (dots) amino acids. 
Below the sequences, residues important for DNA binding and bending are shown with blue open 
triangles and green closed triangles, respectively. Brown brackets demarcate the three D-helices 
(H1, H2, and H3) that secondarily structure the DNA-binding domain. Key amino acids in the N-
terminal and C-terminal nuclear localization signal sequences (NLS) and nuclear export signal 
sequence (NES) are shown with continued lines and are linked with dotted lines.  
(C) Comparison of the HMG domain sequences of all human SOX proteins. Sequence accession 
numbers are listed in Table S2.  
 
Figure 6. Consequences of Missense Mutations on SOX4 Protein Level and Activity 
(A) Western blot of nuclear (N) and cytoplasmic (C) extracts from COS-1 cells transiently 
transfected with expression plasmids encoding wild-type (WT) or variant (Phe66Leu, Ala112Pro, 
Ile59Ser or Lys105Asn) SOX4 proteins fused at the N-terminus with a 3FLAG epitope. The 
proteins were identified using anti-FLAG antibody. The Mr of protein standards is indicated in k 
units. Note that each SOX4 protein exhibited the expected Mr of approximately 75 k. The bottom 
panel is a longer exposure of the same blot as in the top panel. It is limited to the SOX4 protein 
region and shows that SOX4 protein was present in all nuclear extracts, but at a lower level than 
in cytoplasmic extracts. Variant SOX4 proteins did not show significant differences in nuclear 
localization compared to wild-type SOX4 when several independent experiments were 
considered. 
(B) EMSA comparing the binding efficiency of SOX4 wild-type and variants. The cell extracts were 
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the same as in panel A, but also included negative controls without SOX4 (-). The arrow indicates 
the complex formed between wild-type SOX4 and the DNA probe. 
(C) $VVD\RI WKHDELOLW\RI WKH IRXUFDVHV¶62;YDULDQWV WRDFWLYDWH WUDQVFULSWLRQ COS-1 cells 
were transiently transfected with a 6FXO-p89-Luc reporter, a pSV-beta-galactosidase plasmid, 
and expression plasmids for no protein (-), wild-type or variant SOX4, and POU3F2. Reporter 
activities are presented as the mean ± standard deviation obtained from triplicates for each 
condition. They were normalized for transfection efficiency and are reported as fold increase 
relative to the activity of the reporter in the absence of SOX4 and POU3F2. The presence (+) or 
absence (-) of SOX4 and POU3F2 plasmid is indicated beneath the bars. These data were 
reproduced in more than three independent experiments.  
(D) Assay of the ability of the twelve gnomAD SOX4 HMG-domain missense variants to activate 
transcription. COS-1 cells were transfected as described in panel C and using SOX4 and POU3F2 
expression plasmids as shown in the figure. Data were calculated and are presented as in panel 
C. They were reproduced in four independent experiments. A western blot showing that similar 
amounts of SOX4 protein were made in all conditions is presented in Figure S3.  
 35 
 
Table 1. Summary of Demographic, Genetic and Clinical Characteristics of the 
Subject Cohort.  
Parentheses, percentiles. Brackets, standard deviations. N.D., not determined. OFC, 
occipitofrontal head circumference. 
 
Subject 1 Subject 2 Subject 3 Subject 4 
Gender 
Age 
Ancestry 
Male 
4 years 8 months 
Italian 
Male 
6 years 8 months 
Scottish-Hungarian 
Female 
6 years 0 month 
French 
Female 
6 years 10 months 
Scottish 
SOX4 variant p.Phe66Leu p.Ala112Pro p.Ile59Ser p.Lys105Asn 
Growth delay 
 
Height: 100.7 cm (10th) 
Weight: 15.0 kg (8th) 
OFC: 47.6 cm (1st) [-
2.5 SD]  
N.D. 
14.8 kg (1st) [-3.66 
SD] 
48.3 cm (0.4th) [-2.8 
SD] 
98.6 cm (6th) 
14.6 kg (9th) 
50 cm (12th) [-0.65 
SD] 
109.7 cm (3rd) 
17 kg (3rd) 
52.3 c (45th) [-0.1 
SD] 
Speech delay First words at 4 years No speech Delayed speech 
at 3 years  
First words at 2 
years 
Walking delay First steps at 27 
months 
Not ambulant  No delay  First steps at 21 
months 
Intellectual 
and 
neurological 
delay 
Mild ID (IQ: 68); 
epilepsy; myelination 
delay  
Severe ID; spastic 
quadriparesis; 
cerebellar atrophy; 
patchy changes in 
cerebral white matter 
Very mild learning 
difficulties 
Learning difficulties 
requiring 
educational support 
(IQ: 52) 
 
Facial 
dysmorphism 
Microbrachycephaly; 
epicanthus; stellate iris 
pattern; short nose; 
upturned nares; wide 
mouth with cupid bow; 
and posteriorly rotated 
ears 
Microcephaly; 
trigonocephaly; 
metopic ridge; 
epicanthic folds; 
infra-orbital folds; and 
wide mouth with 
cupid bow 
Deep-set eyes; 
infra-orbital 
grooves; 
upturned nares; 
wide mouth with 
cupid bow and full 
lips 
Deep-set eyes; 
infra-orbital creases; 
malar flattening, 
upturned nares; 
wide mouth with 
cupid bow, and full 
lips; and posteriorly 
rotated ears 
Hand and foot 
malformation 
Bilateral 5th finger 
clinodactyly 
Congenital vertical 
talus; bilateral 5th 
finger clinodactyly 
Mild 5th finger 
clinodactyly; 
dysplastic 5th 
toenails 
Bilateral 5th finger 
clinodactyly; mild 
camptodactyly 
Hypotonia  Mild, generalized Truncal hypotonia Not detected Not detected 
Other 
abnormal 
features 
Ventricular septal 
defect; feeding 
difficulties and 
constipation; 
strabismus and 
keratoconus 
Feeding difficulties; 
laryngomalacia; 
delayed secondary 
dentition 
None detected None detected 
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Table 2. Pathological Missense Variants in SRY and Other SOX Protein Residues 
Matching the SOX4 Variants Identified in Four Individuals with ID in this Study 
 
Protein Variant Phenotype Reference 
SOX4  F66L   Neurodevelopmental syndrome  This study 
SRY  F67V   Gonadal dysgenesis, XY sex reversal  48 
SOX9  F112L  Campomelic dysplasia 9 
SOX10  F111V Kallmann syndrome 49 
 
SOX4  A112P Neurodevelopmental syndrome This study 
SRY  A113T Gonadal dysgenesis 50 
SOX9  A158T Campomelic dysplasia, XY sex reversal 51 
SOX9  A158V Campomelic dysplasia 52 
SOX10  A157V Waardenburg syndrome type IV 53 
SOX11  A102V Coffin-Siris syndrome 54 
 
SOX4  I59S  Neurodevelopmental syndrome This study 
SRY  V60L   XY sex reversal   55 
 
SOX4  K105N  Neurodevelopmental syndrome  This study  
SRY  K106I   Gonadal dysgenesis  56 
SOX10  K150N +LUVFKVSUXQJ¶VGLVHDVH 57 
 
